Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.59 |
| ▸ | CCR2 | P41597 | 6/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RHOC | P08134 | 3/20 | 0.46 |
| ▸ | RHOA | P61586 | 3/20 | 0.46 |
| ▸ | RBP4 | P02753 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815284 | 0.96 | MGLL (0.56) | MGLLCCR2HSD11B1SMN1; SMN2MEN1 | |
| SCHEMBL14814826 | 0.92 | HSD11B1 (0.58) | MGLLCCR2HSD11B1SMN1; SMN2MEN1 | |
| SCHEMBL14815178 | 0.90 | MGLL (0.56) | MGLLHSD11B1MEN1KMT2AHPGD | |
| SCHEMBL14815463 | 0.88 | HSD11B1 (0.56) | MGLLCCR2HSD11B1MEN1KMT2A | |
| SCHEMBL14815309 | 0.84 | MEN1 (0.47) | CCR2HSD11B1MEN1KMT2ARBP4 | |
| SCHEMBL14815442 | 0.83 | MGLL (0.52) | MGLLHSD11B1SMN1; SMN2LMNAPOLB | |
| SCHEMBL14815226 | 0.81 | HSD11B1 (0.56) | MGLLHSD11B1MEN1KMT2APOLB | |
| SCHEMBL14815248 | 0.78 | CACNA1B (0.49) | HSD11B1SMN1; SMN2POLBHPGD | |
| SCHEMBL14815455 | 0.77 | MGLL (0.49) | MGLLMEN1KMT2ARHOCRHOA | |
| SCHEMBL14814764 | 0.75 | MGLL (0.51) | MGLLHSD11B1SMN1; SMN2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | MGLL 4703/4885CCR2 2651/4885HSD11B1 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.